

Arthur J A T Braat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6618419/publications.pdf>

Version: 2024-02-01

64
papers

1,272
citations

361296

20
h-index

395590

33
g-index

65
all docs

65
docs citations

65
times ranked

1079
citing authors

#	ARTICLE	IF	CITATIONS
1	Indocyanine green versus technetium ^{99m} with blue dye for sentinel lymph node detection in early-stage cervical cancer: A systematic review and meta-analysis. <i>Cancer Reports</i> , 2022, 5, e1401.	0.6	10
2	A compact and mobile hybrid C-arm scanner for simultaneous nuclear and fluoroscopic image guidance. <i>European Radiology</i> , 2022, 32, 517-523.	2.3	6
3	Intraarterial Administration Boosts ¹⁷⁷ Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients. <i>Journal of Nuclear Medicine</i> , 2022, 63, 406-409.	2.8	13
4	Lung Dose Measured on Postradioembolization ⁹⁰ Y PET/CT and Incidence of Radiation Pneumonitis. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1075-1080.	2.8	5
5	Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy. <i>EJNMMI Research</i> , 2022, 12, 7.	1.1	3
6	Value of routine cytokeratin immunohistochemistry in detecting low volume disease in cervical cancer. <i>Gynecologic Oncology</i> , 2022, 165, 257-263.	0.6	3
7	Challenges in Von Hippel-Lindau's disease: PRRT in patients on hemodialysis. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2022, 2022, .	0.2	0
8	Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1700-1710.	3.3	10
9	¹⁶⁶ Holmium- ^{99m} Technetium dual-isotope imaging: scatter compensation and automatic healthy-liver segmentation for ¹⁶⁶ Holmium radioembolization dosimetry. <i>EJNMMI Physics</i> , 2022, 9, 30.	1.3	2
10	Safety and Efficacy of ¹⁶⁶ Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1891-1898.	2.8	11
11	Holmium-166 Radioembolization: Current Status and Future Prospective. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 1634-1645.	0.9	26
12	Baseline Imaging Derived Predictive Factors of Response Following [¹⁷⁷ Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis. <i>Biomedicines</i> , 2022, 10, 1575.	1.4	10
13	The Evolving Role of Radioembolization in the Treatment of Neuroendocrine Liver Metastases. <i>Cancers</i> , 2022, 14, 3415.	1.7	3
14	Dose-Effect Relationships of ¹⁶⁶ Ho Radioembolization in Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 272-279.	2.8	32
15	Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization: a prospective, within-patient randomized study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1658-1668.	3.3	13
16	Holmium-166 Radioembolization in NET Patients. , 2021, , 241-250.		0
17	Yttrium-90 SIRT in NET. , 2021, , 231-239.		0
18	Current Status and Future Direction of Hepatic Radioembolisation. <i>Clinical Oncology</i> , 2021, 33, 106-116.	0.6	16

#	ARTICLE	IF	CITATIONS
19	Gamma camera characterization at high holmium-166 activity in liver radioembolization. EJNMMI Physics, 2021, 8, 22.	1.3	9
20	[18F]FDG and [18F]FES positron emission tomography for disease monitoring and assessment of anti-hormonal treatment eligibility in granulosa cell tumors of the ovary. Oncotarget, 2021, 12, 665-673.	0.8	4
21	Doseâ€“Response and Doseâ€“Toxicity Relationships for Glass ⁹⁰ Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer. Journal of Nuclear Medicine, 2021, 62, 1616-1623.	2.8	36
22	^{99m} Tc-HDP bone scintigraphy confirming parathyroid hormone-related peptide paraneoplastic syndrome in metastatic breast cancer. Lancet Oncology, The, 2021, 22, e216.	5.1	0
23	Competition (â€“Stealâ€“™ Phenomenon) between [68Ga]Ga-PSMA-11 Uptake in Prostate Tumor Tissue Versus Healthy Tissue. Pharmaceutics, 2021, 13, 699.	2.0	2
24	The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: A systematic review. Gynecologic Oncology, 2021, 162, 517-525.	0.6	5
25	⁹⁰ Y radioembolization in the treatment of neuroendocrine neoplasms: Results of an international multicenter retrospective study.. Journal of Nuclear Medicine, 2021, , jnumed.121.262561.	2.8	10
26	A Rapid and Safe Infusion Protocol for ¹⁷⁷ Lu Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine, 2021, 62, 816-822.	2.8	4
27	Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study. European Journal of Hybrid Imaging, 2021, 5, 22.	0.6	4
28	First experiences with ¹⁷⁷ Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer. EJNMMI Research, 2021, 11, 126.	1.1	15
29	Radioembolization with ⁹⁰ Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy. CardioVascular and Interventional Radiology, 2020, 43, 246-253.	0.9	37
30	The superior predictive value of ¹⁶⁶ Ho-scout compared with ^{99m} Tc-macroaggregated albumin prior to ¹⁶⁶ Ho-microspheres radioembolization in patients with liver metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 798-806.	3.3	62
31	The Efficacy of Coil Embolization to Obtain Intrahepatic Redistribution in Radioembolization: Qualitative and Quantitative Analyses. CardioVascular and Interventional Radiology, 2020, 43, 391-401.	0.9	4
32	Feasibility of imaging ⁹⁰ Y microspheres at diagnostic activity levels for hepatic radioembolization treatment planning. Medical Physics, 2020, 47, 1105-1114.	1.6	13
33	Lutetium-177-PSMA therapy for prostate cancer patientsâ€“aâ€“brief overview of the literature. Tijdschrift Voor Urologie, 2020, 10, 141-146.	0.1	8
34	Evaluation of the Safety and Feasibility of Same-Day Holmium-166 -Radioembolization Simulation and Treatment of Hepatic Metastases. Journal of Vascular and Interventional Radiology, 2020, 31, 1593-1599.	0.2	6
35	Verification Study of Residual Activity Measurements After Yttrium-90 Radioembolization with Glass Microspheres. CardioVascular and Interventional Radiology, 2020, 43, 1378-1383.	0.9	1
36	Toxicity and dosimetry in SORAMIC study. Journal of Hepatology, 2020, 73, 734-735.	1.8	3

#	ARTICLE	IF	CITATIONS
37	Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1035-1043.e2.	0.2	49
38	Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 69</i>		
39	Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2020, 21, 561-570.	5.1	48
40	Personalized Dosimetry: The Way to Limit Hepatotoxicity. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 515-516.	0.2	1
41	Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. <i>Journal of Urology</i> , 2020, 203, 537-545.	0.2	79
42	⁶⁸ Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with ¹⁷⁷ Lu-PSMA-617. <i>EJNMMI Research</i> , 2020, 10, 18.	1.1	46
43	Quantitative ¹⁶⁶ Ho-microspheres SPECT derived from a dual-isotope acquisition with ^{99m} Tc-colloid is clinically feasible. <i>EJNMMI Physics</i> , 2020, 7, 48.	1.3	10
44	Simultaneous ¹⁶⁶ Ho/ ^{99m} Tc dual-isotope SPECT with Monte Carlo-based downscatter correction for automatic liver dosimetry in radioembolization. <i>EJNMMI Physics</i> , 2020, 7, 13.	1.3	12
45	Intra-Arterial Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor Liver Metastases. <i>Digestive Disease Interventions</i> , 2019, 03, 081-090.	0.3	9
46	The value of yttrium-90 PET/CT after hepatic radioembolization: a pictorial essay. <i>Clinical and Translational Imaging</i> , 2019, 7, 303-312.	1.1	10
47	Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2270-2279.	3.3	52
48	Holmium-166 Microsphere Radioembolization of Hepatic Malignancies. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 237-243.	2.5	64
49	Will ¹⁷⁷ Lu-DOTATATE Treatment Become More Effective in Salvage Meningioma Patients, When Boosting Somatostatin Receptor Saturation? A Promising Case on Intra-arterial Administration. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1649-1652.	0.9	17
50	Radioembolisation with ^{90Y} microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. <i>Hpb</i> , 2019, 21, 773-783.	0.1	31
51	First Experience With ¹⁷⁷ Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands. <i>Clinical Nuclear Medicine</i> , 2019, 44, 446-451.	0.7	22
52	Radioembolization with ^{90Y} Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 413-425.	0.9	70
53	No Need for Prophylactic Abdominal Ice Packing During Radioembolization. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 200-201.	0.9	2
54	Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: A cohort study. <i>European Radiology</i> , 2018, 28, 920-928.	2.3	53

#	ARTICLE	IF	CITATIONS
55	Impact of external cooling with icepacks on 68Ga-PSMA uptake in salivary glands. EJNMMI Research, 2018, 8, 56.	1.1	54
56	The physics of radioembolization. EJNMMI Physics, 2018, 5, 22.	1.3	65
57	Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). BMC Gastroenterology, 2018, 18, 84.	0.8	32
58	Gastrointestinal stromal tumour detection with somatostatin receptor imaging, 68Ga-HA-DOTATATE PET-CT. Lancet Oncology, The, 2017, 18, e185.	5.1	4
59	Estimation of lung shunt fraction from simultaneous fluoroscopic and nuclear images. Physics in Medicine and Biology, 2017, 62, 8210-8225.	1.6	2
60	Adequate SIRT activity dose is as important as adequate chemotherapy dose. Lancet Oncology, The, 2017, 18, e636.	5.1	16
61	⁹⁰ Y Hepatic Radioembolization: An Update on Current Practice and Recent Developments. Journal of Nuclear Medicine, 2015, 56, 1079-1087.	2.8	77
62	Hepatic Radioembolization as a Bridge to Liver Surgery. Frontiers in Oncology, 2014, 4, 199.	1.3	23
63	Cardiac sympathetic innervation and cardiac resynchronization therapy. Heart Failure Reviews, 2014, 19, 567-573.	1.7	11
64	Holmium-166 Radioembolization. Digestive Disease Interventions, 0, 05, .	0.3	0